Even as two amyloid immunotherapies are in clinical use, scientists still have many questions about how these antibodies affect the brain. Neuropathology and biomarker data from treated patients are ...

More than two decades have passed since William Pardridge of the University of California, Los Angeles, used the analogy of a Trojan horse to describe molecular transport shuttles that can sneak ...

As amyloid immunotherapy enters clinical care in more countries, providers the world over are eager for more information on how well it works, and especially how safe it is. To collect such data in ...

This humanized IgG1 antibody inhibits an immune checkpoint protein called programmed death ligand, aka PD-L1, stimulating the immune system. Checkpoint inhibitors, including other antibodies, are ...

reactive to aa 1-16 of Aβ and to APP; reacts to the abnormally processed isoforms, as well as precursor forms ...

A top researcher’s fall from grace sends shock waves through the scientific community. Such is the case with neuropathologist Eliezer Masliah, who stands accused of image falsification spanning 26 ...

Biogen’s hopes for a quick regulatory approval of its anti-Aβ antibody aducanumab may be dimming. An advisory panel convened by the U.S. Food and Drug Administration was unimpressed by the evidence ...

The top-line results last September from Eisai’s Phase 3 trial of the anti-amyloid antibody lecanemab galvanized the field, but scientists said they needed to see the data before passing judgement.

Researchers led by Nicholas Ashton at the University of Gothenburg, Sweden, recently reported that ALZpath Inc.’s plasma phospho-tau217 assay detected amyloid and tau positivity with 92 to 97 percent ...

For 30 years, APOE4 has ranked as the strongest genetic risk factor for Alzheimer’s disease, with two copies boosting the odds up to 15-fold. Now, scientists argue that people with two APOE4 alleles ...

As the baby boom generation reaches its hopefully golden years, scientists have been projecting a doubling of dementia cases in the U.S. by 2050, alarming health care agencies, the public, and health ...

Missense mutations that derail SORL1 trafficking cause AD. Other variants shift AD risk in East Asians and Europeans. SORL1 dysfunction messes with endosomes in neurons, and with lysosomes in ...